Clinical trials: Intradermal (ID) Vaccination Device

Intradermal (ID) Vaccination Device

Intradermal Rabies Immunization Using NanoJect: A Comparative Study

• Completed
• Age: 18 to 50 years
• Phase 1
• Vaccines
• Injection or infusion

The study is planned as a single-center, randomized, double-blind placebo-controlled, comparative Phase I, first-in-man study to assess the safety and tolerability of the NanoJect™ device, and the immunogenicity of the rabies…

Trial name

NCT02538185

Testing

NanoJect device (DebioJect™), Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus), Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)

Volunteers

66 people, healthy volunteers welcome

Sponsor

University of Lausanne Hospitals